higher than controls (p<0001 and p<0001), but platelet lifespan studies were normal. There was no correlation with disease activity. Patients with inflammatory bowel disease have abnormal platelet activity, which may contribute to the inflammatory process. (Gut 1993; 34: 247-251) An increased risk of major thromboembolism has been described in patients with inflammatory bowel disease'" with incidences as high as 39% in some postmortem studies.4 Young patients with active ulcerative colitis appear to be particularly susceptible with significant mortality.' 2 A climate of blood hypercoaguability has been described in patients with inflammatory bowel disease (IBD) and more recently, thrombosis, vasculitis, and tissue infarction have been proposed as contributing factors in Crohn's disease. 7 Examination of the clotting cascade has revealed significant abnormalities8"'2 and abnormalities of fibrinolysis have also been described'3"'5 but little attention has been focused on the role of platelets which are known to contribute to all aspects of normal haemostasis. We have therefore examined the risk of thromboembolic disease and undertaken a study of platelet function, in patients with inflammatory bowel disease attending a gastroenterology follow up clinic.
reactive protein, albumin, al acid glycoprotein, haemoglobin, and erythrocyte sedimentation rate). These were used to confirm disease activity status, but if a clear discrepancy arose then more emphasis was given to these indicators and disease activity estimated by an independent observer. A 60 ml venous blood sample was obtained with minimal stasis after a fat free breakfast, of which 20 ml aliquot was allowed to stand for measurement of C reactive protein, ctI acid glycoprotein, and anticardiolipin antibodies. The remainder was immediately anticoagulated using freshly prepared 3-8% disodium citrate solution (at a ratio of nine parts blood to one part anticoagulant).
A separate 11 5 ml sample of blood was also taken, of which 9 ml was placed directly in a precooled tube containing 0 95 ml of EDTA and a 0 04 M solution of indomethacin (for measurement of thromboxane B2 and 6-keto-prostaglandin Fla) and the remaining 2 (Table II) Eight patients were found to have a previous history of thromboembolism and in seven there were recurrent complications.
Two patients died from causes directly attributable to thromboembolic complications over the 18 month follow up period.
PLATELET MORPHOLOGY AND NUMBER (Table III) Eight of 40 were non-reproducible and therefore impossible to interpret. In those patients tested there was no significant abnormality of adhesion detected and no difference between patients and controls. (Table IV) (a) Spontaneous platelet aggregation. Eight of nine patients whose disease activity status changed during the course of the study retained this abnormality. Two patients who were taking non-steroidal anti-inflammatory drugs (which exert an anti-aggregatory effect) at the time of study, also showed SPAG. Seven of eight patients with previous thromboembolism showed SPAG.
(b) Aggregation studies with aggregating agents. A further 11 patients in the Crohn's disease group and nine in the ulcerative colitis group (including one in the panproctocolectomy group) had marked sensitivity of platelets to low concentrations of aggregating agents when compared with controls (this arbitrarily being defined as more than a threefold difference in endpoint dilution of aggregating agent). (Fig 2) . There was a highly significant difference between patients and controls for each of the three aggregating agents, adenosine diphosphate, collagen, and arachidonic acid (p<0 001, p<0 001, and p<0 001). There was no difference for ristocetin, or between patients with Crohn's disease and ulcerative colitis and no correlation with disease activity.
(c) Gel filtered platelets. Gel filtration of PRP produced on average a platelet yield of approximately 60%. The platelets functioned adequately in 12 of 20 (60%) patients with SPAG when resuspended in autologous plasma. The platelets from six patients (50%) showed SPAG when suspended in ABO compatible control plasma, even with PRP platelet counts of less than 1OOx 109/1. Conversely, the plasma from the same patients was not seen to induce SPAG in control PRP.
BTG, TBXB2, AND 6-KOTO-PROSTAGLANDIN F1I (Table V) Plasma thromboxane B2 and a -thromboglobulin were significantly higher in patients than in controls (p<0 001, p<0 001). There was no difference between patients with Crohn's disease and those with ulcerative colitis and no correlation with disease activity. There was no significant difference between the patients and control, groups in the 6-keto-prostaglandin Flo levels Plasma thromboxane B2, 6-keto-prostaglandin F1to, r) thromboglobulin, and the ratio of thromboxane B2 to 6-keto-prostaglandin Flu, in patients and controls. *p<0-O0l, tp<0 OOl. and in the TBXB2:6-keto-prostaglandin Fla ratio (Fig 3) .
PLATELET LIFESPAN
The in vitro aggregation response of patients' PRP to 10 FtM ADP after separation and labelling with "'"In oxide compared favourably with that of controls. Hepatic sequestration after reinjection reached a plateau and matched the curve for the blood pool in all patients. These results suggest that minimal damage was incurred by the platelets as a result of the separation and labelling procedures. 20 The platelet life span in all 10 patients was normal (seven to ten days), although two patients had borderline low results (Fig 4) . Screening of the abdomen for abnormal uptake showed no evidence of sequestration of platelets in the bowel wall at sites of active disease. There was no difference in platelet survival between the Crohn's disease and ulcerative colitis groups and no correlation with platelet count or spontaneous platelet aggregation.
Discussion
The association between thromboembolism and inflammatory bowel disease was first described by Bargen and Barker in 1936. The work, based mainly on clinical observation, described severe and life threatening thromboembolism, particularly in young patients with active ulcerative colitis, and the authors concluded that a coagulopathy was to blame and that it probably related to 'platelet function or the ease in which thromboplastin in generated. Fibrinolysis has also been shown to be abnormal in patients with inflammatory bowel disease,'3-'5 with raised levels of plasminogen activator inhibitor and decreased tissue plasminogen activator having been described, although no correlation with disease activity was found in this instance. Platelets have received less attention, which is surprising considering the essential role they play in normal haemostasis and the contribution they make to normal coagulation and fibrinolysis. Although abnormalities have been described,22 24 studies have generally been small and inconclusive.
We have shown a significant risk of recurrent thromboembolism in patients with inflammatory bowel disease (8/104) and in most cases this complication occurred during disease quiescence (and in some cases preceded the diagnosis of the underlying bowel disorder). Platelet aggregation and in particular spontaneous aggregation was found to be markedly active in a high proportion of patients and spontaneous platelet aggregation was observed in seven of the eight patients with previous thromboembolism. Spontaneous platelet aggregation has been described in other disorders associated with thromboembolic disease.25-27 In addition, circulating plasma levels ofthe platelet release proteins 13 thromboglobulin and thromboxane B2 were also found to be raised, providing in vivo evidence for increased platelet activation. No correlation between abnormal platelet function and disease activity was observed and the features of abnormal platelet function were retained in patients who experienced a change in disease activity status during the study period. In addition, patients with ulcerative colitis who had undergone previous panproctocolectomy also showed these abnormalities. The mean platelet volume of patients especially of those with SPAG, was generally lower than that of controls. This would tend to rule out the possibility of an abnormal population of younger, more active (and larger) platelets circulating in patients with inflam- 1001-z matory bowel disease because of high platelet turnover.29 Platelet life span was normal in all 10 patients studied (although two patients had borderline low values), which suggests that the increased platelet consumption taking place is of a low grade nature and more likely to occur at the microvascular level. These results would support the hypothesis of a small vessel vasculitic/thrombotic cause in patients with Crohn's disease,7 although in our study patients with ulcerative colitis were found to be equally at risk.
Our studies with gel filtered platelets suggest that the abnormalities observed are due to an inherent platelet defect and not due to circulating platelet activators, although potential candidates for circulating activators would have to include bacterial lipopolysaccharides (which have been shown to include surface tissue factor expression in monocytes, which is a potent activator of platelets)'2 29 and bacterial toxins such as verotoxins (which have been shown to induce SPAG in children with the haemolytic uraemic syndrome). 0 It is interesting that two patients currently taking cyclooxygenase inhibiting drugs (non-steroidal anti-inflammatory drugs) also had SPAG, implying that prostaglandin synthesis is not a primary mechanism in the development of this phenomenon.
In 
